Pulmonary toxicity due to chemotherapy. How is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?

Isamu Okamoto, Moritaka Suga

Research output: Contribution to journalEditorial

3 Citations (Scopus)
Original languageEnglish
Pages (from-to)926-927
Number of pages2
JournalInternal Medicine
Volume42
Issue number10
DOIs
Publication statusPublished - Jan 1 2003

Fingerprint

gemcitabine
Quinazolines
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Lung Diseases
Lung Neoplasms
Drug Therapy
Lung
Therapeutics
gefitinib

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Pulmonary toxicity due to chemotherapy. How is the risk and benefit from ZD1839 treatment against non-small cell lung cancer? / Okamoto, Isamu; Suga, Moritaka.

In: Internal Medicine, Vol. 42, No. 10, 01.01.2003, p. 926-927.

Research output: Contribution to journalEditorial

@article{6b4fc2b9ffc2413aaea1f0c5a3022fac,
title = "Pulmonary toxicity due to chemotherapy. How is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?",
author = "Isamu Okamoto and Moritaka Suga",
year = "2003",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.42.926",
language = "English",
volume = "42",
pages = "926--927",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "10",

}

TY - JOUR

T1 - Pulmonary toxicity due to chemotherapy. How is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?

AU - Okamoto, Isamu

AU - Suga, Moritaka

PY - 2003/1/1

Y1 - 2003/1/1

UR - http://www.scopus.com/inward/record.url?scp=0242606878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242606878&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.42.926

DO - 10.2169/internalmedicine.42.926

M3 - Editorial

C2 - 14606701

AN - SCOPUS:0242606878

VL - 42

SP - 926

EP - 927

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 10

ER -